Lilly(US:LLY) NBC Newsยท2025-08-08 01:00Pharmaceutical Development & Clinical Trials - Eli Lilly is preparing to submit a weight loss pill for FDA approval by the end of the year [1] - Phase 3 clinical trials showed meaningful body weight decrease and improvements in cholesterol and blood pressure [2] - In trials targeting overweight adults, participants on the highest dose lost up to 27 pounds (approximately 12247 grams) over 72 weeks [3] - One participant lost 40 pounds (approximately 18143 grams) during the trial and reported a reduction in "food noise" [3] - The weight loss pill is a GLP-1 medication, similar to Ompic and Zepbound [4] Market & Analyst Perspective - Trial results for the pill fell short of some analyst predictions, leading to a stock market price decrease for Eli Lilly [4] - Weight loss doctors believe the pill will be an important option for some patients, as not everyone needs to lose the same amount of weight [4][5] Pill Advantages & Production - The pill offers convenience compared to injections [5] - The pill may not have the same shortage problems as injections, as it doesn't require refrigeration, sterile filling of syringes, or an injection device [6] - Eli Lilly states it is already manufacturing the pill and has a stockpile to meet demand [6] - With FDA approval, Eli Lilly anticipates the pill could be available in pharmacies by next year [6]